Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs

The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Butle, Ashwin, Joshi, Asim, Noronha, Vanita, Prabhash, Kumar, Dutt, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236545/
https://www.ncbi.nlm.nih.gov/pubmed/33993094
http://dx.doi.org/10.1016/j.tranon.2021.101111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236545/
https://www.ncbi.nlm.nih.gov/pubmed/33993094
http://dx.doi.org/10.1016/j.tranon.2021.101111

Ejemplares similares